Skip to content

Study · Animal study (in vivo) · 2014

2 results

Expression, purification, and biological activity of the recombinant pramlintide precursor.

Hu H, Xiang Q, Liu H, Qu H, Tang X, Xiao X, Zhang Q, Su Z, Huang Y

Applied microbiology and biotechnology15 Apr 2014Cited by 3 (Europe PMC)

PMID24728756 (opens in a new tab)DOI10.1007/s00253-014-5699-2 (opens in a new tab)PepBankPUB-24728756
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In an animal gastric emptying model, chemically synthesized pramlintide and PAG had almost the same biological activity.

    In plain wordsIn animals, chemically synthesized pramlintide and PAG had almost the same activity in a gastric emptying model.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Direction not reportedGastric emptying biological activity
    Study

    n: not reported in source

    Animal gastric emptying model
    Comparator
    Pramlintide precursor with C-terminal glycine (PAG)
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Based on an L6 myoblast cell model in vitro and an animal model of gastric emptying in vivo, the results of activity revealed that PAG showed a lower biological activity in vitro but has almost the same activity as the chemically synthesized pramlintide in vivo.
  2. 02LabIn vitro (cells)Activity measurement

    In L6 myoblast assays, chemically synthesized pramlintide had greater biological activity than its glycine-extended precursor PAG.

    In plain wordsIn cells, chemically synthesized pramlintide had greater biological activity than its precursor PAG.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseBiological activity in vitro
    Study

    n: not reported in source

    L6 myoblast cells
    Comparator
    Pramlintide precursor with C-terminal glycine (PAG)
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Based on an L6 myoblast cell model in vitro and an animal model of gastric emptying in vivo, the results of activity revealed that PAG showed a lower biological activity in vitro but has almost the same activity as the chemically synthesized pramlintide in vivo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.